Evaluation of the pharmacological repositioning of semaglutide in the weight loss process: A literature review
DOI:
https://doi.org/10.33448/rsd-v13i11.47305Keywords:
Weight loss; Obesity; Safety.Abstract
Obesity, a condition that has tripled globally since the 1970s, currently affects about 40% of the adult population, with 13% classified as obese. This increase is associated with a higher risk of cardiovascular complications, the leading cause of death among obese individuals, and also generates high healthcare costs. In the treatment context, semaglutide, a GLP-1 analogue, emerges as a promising innovation for weight loss.Initially approved for the treatment of type 2 diabetes, semaglutide has also shown efficacy in reducing body weight. The drug works by regulating hyperglycemia and decreasing appetite, especially when combined with diet and physical exercise. Studies such as STEP 1 and STEP 2 demonstrate significant weight loss in populations with obesity and diabetes. However, gastrointestinal side effects, such as nausea and vomiting, are common concerns, as well as the high cost of treatment.Semaglutide offers an effective alternative to medications like orlistat and liraglutide, with the advantage of weekly administration. However, long-term safety and financial accessibility remain significant challenges that require continuous attention in research and clinical practice. This article aims to evaluate, through a literature review, the pharmacological repositioning of semaglutide as a weight-loss agent, discussing its mechanisms of action, clinical efficacy, safety, and potential impact on obesity management in different populations. The article was conducted based on a narrative literature review.
References
Carris, N. W., Wallace, S., DuCoin, C. G., Mhaskar, R., Stern, M., & Bunnell, B. (2024). Interrupção da semaglutida após perda de peso: estratégia para manutenção do peso e um possível novo efeito colateral. Jornal canadense de fisiologia e farmacologia, 102(6), 391–395. https://doi.org/10.1139/cjpp-2023-0464
Casarin, S. T., Porto, A. R., Gabatz, R. I. B., Bonow, C. A., Ribeiro, J. P., & Mota, M. S. (2020). Tipos de revisão de literatura: considerações das editoras do Journal of Nursing and Health / Types of literature review: considerations of the editors of the Journal of Nursing and Health. Journal of Nursing and Health, 10(5). https://doi.org/10.15210/jonah.v10i5.19924
Chao, A. M., Wadden, T. A., Berkowitz, R. I., & Fernstrom, M. H. (2023). Semaglutide for the treatment of obesity. Trends in Cardiovascular Medicine, 33(3), 159-166. https://doi.org/10.1016/j.tcm.2022.08.007
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023). Farmacoterapia da obesidade: uma atualização sobre os medicamentos disponíveis e os medicamentos sob investigação. EClinicalMedicine, 58, 101882. https://doi.org/10.1016/j.eclinm.2023.101882
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Rosenstock, J., & Wadden, T. A. (2021). Semaglutide as a tool for weight loss in obese patients: A review. Diabetes, Obesity and Metabolism, 23(5), 1132-1140. https://doi.org/10.1111/dom.14335
El Meouchy, P., Wahoud, M., Allam, S., Chedid, R., Karam, W., & Karam, S. (2022). Hipertensão relacionada à obesidade: patogênese, características e fatores de controle. Revista internacional de ciências moleculares, 23(20), 12305. https://doi.org/10.3390/ijms232012305
Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Resultados de perda de peso associados ao tratamento com semaglutida para pacientes com sobrepeso ou obesidade. Rede JAMA aberta, 5(9), e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., & Wharton, S. (2020). Safety and tolerability of semaglutide for weight loss. Obesity (Silver Spring), 28(10), 1963-1972. https://doi.org/10.1002/oby.22986
Montalvan, D. E. A., Fuenmayor, C. F. P., & Benavides, R. E. O. (2022). Relação entre a droga semaglutida e a redução de peso em pacientes com obesidade: Uma revisão sistemática. Revista Salud La Paz, 5(15), 698-714. https://doi.org/10.25214/rs.v5i15.1028
Ojeniran, M., Manacero, S. A., Tandon, P., & Wong, J. (2021). Semaglutide for weight loss. Canadian Family Physician, 67(11), 842-842.
Quddos, F., Hubshman, Z., Tegge, A., Sane, D., Marti, E., Kablinger, A. S., Gatchalian, K. M., Kelly, A. L., DiFeliceantonio, A. G., & Bickel, W. K. (2023). A semaglutida e a tirzepatida reduzem o consumo de álcool em indivíduos com obesidade. Relatórios científicos, 13(1), 20998. https://doi.org/10.1038/s41598-023-48267-2
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., & Dicker, D. (2021). Effect of semaglutide on cardiovascular outcomes in patients with overweight or obesity. Cardiovascular Diabetology, 20(1), 1-11. https://doi.org/10.1186/s12933-021-01298-w
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022). Wegovy (semaglutide): A new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70(1), 5-13. https://doi.org/10.1136/jim-2021-001908
Smits, M. M., & Van Raalte, D. H. (2021). Segurança da Semaglutida. Fronteiras em endocrinologia, 12, 645563. https://doi.org/10.3389/fendo.2021.645563
Solomon, S. D., Ostrominski, J. W., Wang, X., Shah, S. J., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Verma, S., Abildstrøm, S. Z., Nygaard Einfeldt, M., Rasmussen, S., Abhayaratna, W. P., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ito, H., Merkely, B., Núñez, J., Senni, M., ... Comitês e Investigadores do Estudo STEP-HFpEF (2024). Efeito da Semaglutida na Estrutura e Função Cardíaca em Pacientes com Insuficiência Cardíaca Relacionada à Obesidade. Jornal do Colégio Americano de Cardiologia, 84(17), 1587–1602. https://doi.org/10.1016/j.jacc.2024.08.021
Tan, H. C., Dampil, O. A., & Marquez, M. M. (2022). Efficacy and safety of semaglutide for weight loss in obesity without diabetes: A systematic review and meta-analysis. Journal of the ASEAN Federation of Endocrine Societies, 37(2), 65. https://doi.org/10.15605/jafes.037.02.02
Wharton, S., Astrup, A., Endahl, L., Leeds, S. G., Van Gaal, L., Müller, T. D., & Pi-Sunyer, X. (2022). Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism, 24(1), 94-105. https://doi.org/10.1111/dom.14528
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
Xiang, J., Ding, X. Y., Zhang, W., Zhang, J., Zhang, Y. S., Li, Z. M., Xia, N., & Liang, Y. Z. (2023). Eficácia clínica da semaglutida na perda de peso, composição corporal e força muscular em adultos chineses. Revisão europeia de ciências médicas e farmacológicas, 27(20), 9908–9915. https://doi.org/10.26355/eurrev_202310_34169
Xiang, J., Qin, L., Zhong, J., Xia, N., & Liang, Y. (2023). GLP-1RA Liraglutida e Semaglutida melhoram a atrofia muscular induzida pela obesidade via SIRT1. Diabetes, síndrome metabólica e obesidade: metas e terapia, 16, 2433–2446. https://doi.org/10.2147/DMSO.S425642
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Juliano Policarpio Moura; Filipe Tadeu Pereira Cintra; Lucas Raizama Obeid; Felipe Octávio Rezende; Poliana Peres Ghazale; Murillo de Sousa Pinto
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
